Estrogen receptor alpha (ERa) is a ligand-dependent nuclear receptor that is important in breast cancer genesis, behavior and response to hormone-based therapies. A T7 phage display screen against full-length human ERa, coupled with genome-wide exon arrays, was used to identify RAC3 as a putative ERa co-regulator. RAC3 is a Rho family small GTPase that is associated with cytoskeletal rearrangement. We demonstrate a novel role for nuclear RAC3 as an ERa transcriptional activator, with prognostic implications for metastatic disease. Through in vitro and cell-based studies, RAC3 was shown to exist in a GTP-bound state and act as a ligand specific ERa co-activator of E2-induced transcription. Overexpression of RAC3 induced pro-growth and pro-migratory genes that resulted in increased migration of ERapositive breast cancer cells. Chemical inhibition and genetic knockdown of RAC3 antagonized E2-induced cell proliferation, cell migration and ERa mediated gene expression, indicating that RAC3 is necessary for full ERa transcriptional activity. In agreement with the molecular and cellular data, RAC3 overexpression in ERa-positive breast cancers correlated with a significant decrease in recurrence free survival and a significant increase in the odds ratio of metastasis. In conclusion, RAC3 is a novel ERa co-activator that promotes cell migration and has prognostic value for ERa-positive breast cancer metastasis. RAC3 may also be a useful therapeutic target for ERa-positive breast cancers.
Introduction
Breast cancer is the second leading cause of death among women in North America. Estrogen receptor alpha (ERa) has an important role in breast development, tumorigenesis and treatment (Johnston, 2010) and is a major marker for prognosis and therapeutic response in breast tumors that express ERa (Johnston, 2010) . ERa-positive (ERa þ ) tumors make up the majority of breast cancers and are typically treated with anti-estrogen or aromatase inhibitor therapies to block ERa activity (Johnston, 2010) .
Transcriptional regulation is a complex process that involves multiple transiently associated co-regulatory proteins (Muramatsu and Inoue, 2000) . ERa is a classical nuclear receptor with both genomic and nongenomic functions (Heldring et al., 2007) . Its role in transcription has been studied extensively (Heldring et al., 2007) . A major mechanism of ERa activation is through the binding of estrogen agonists, which cause the receptor to shed chaperone proteins and become transcriptionally active (Heldring et al., 2007) . Since the first ERa interacting proteins were identified (Halachmi et al., 1994) , considerable effort has been devoted to understanding the molecular mechanisms by which ERa activities are mediated by diverse interacting proteins (Hall and McDonnell, 2005) . A number of co-activators and co-repressors have been discovered that have varying degrees of influence on receptor activity (Hall and McDonnell, 2005) . These co-regulators bind differentially to ERa in the presence of structurally diverse ligands, indicating that the control of ERa action is a complex process that involves multiple co-factors (Shang and Brown, 2002) . In addition, multiple regions of ERa interact with these proteins, including the N-terminal domain, which contains the activating function 1 region, and the C-terminal ligand-binding domain, which contains the ligand-sensitive activating function 2 region (Pike, 2006) . Co-regulator interactions are common in the activating function 2 domain and are typically mediated by ligand-induced changes in protein conformation. For estrogen agonists, these conformational changes expose a co-activator-binding pocket that binds the canonical NR binding motif (LXXLL). The activating function 1, activating function 2 and other regions of the protein bind a diverse set of co-regulators that directly or indirectly alter the activity of ERa through multiple mechanisms (Kumar et al., 2005) . Co-activators such as SRC-3 and TRAP220 are overexpressed in some breast cancers and are thought to be an integral part of tumorigenesis (Hall and McDonnell, 2005) . The identification of novel interacting proteins is key to understanding the normal and abnormal regulation of ERa in tissues and cancer.
Like most cancers, breast cancer mortality is not normally caused by the primary tumor, but rather by metastasis of the initial tumor to areas such as the lymph nodes, brain, lung and bone (Minn et al., 2005; Weil et al., 2005) . Although ERa þ tumors have a better short-term prognosis than ERaÀ tumors, a subset of ERa þ tumors metastasize aggressively and the majority of these metastases continue to express ERa (Harrell et al., 2006) . ERa activity likely has an important role in the establishment and control of tumor metastasis, including regulation of cell proliferation, cell motility and cell invasion (Neuman et al., 1997; Prest et al., 2002; Gururaj et al., 2006) . Co-regulators also has a critical role in E2-induced cell proliferation and cell motility (Saji et al., 2005; Lahusen et al., 2009 ). In the current study, we used a phage display screen against full-length human ERa, coupled with genome-wide exon array analyses, to identify and characterize a novel coactivator, RAC3, as an integral component of the E2-induced cell proliferative and migratory pathways.
Rho-family GTPases are overexpressed in a variety of human tumors and have a wide range of roles throughout the cell, including the regulation of cell migration and adhesion, mitosis, regulation of kinase activity and regulation of transcription factors through cell signaling pathways (Baugher et al., 2005; Onesto et al., 2008) . The RAC family of GTPases consists of three members, RAC1, RAC2 and RAC3. RAC2 expression is myeloid specific, whereas RAC1 and RAC3 are highly homologous and are expressed in a variety of tissues including the breast (Mira et al., 2000) . Previous reports implicate RAC1 and RAC3 in breast pathogenesis (Leung et al., 2003; Baugher et al., 2005; Xie and Haslam, 2008) . Most existing data describe RAC3 activity in the cytoplasm and membrane. However, recent reports have shown that Rho family GTPases and their activating proteins are also present in the nucleus (Sandrock et al., 2010) . The role of Rho family GTPases in the nucleus is not well understood. In the current study, we characterize RAC3 as an ERa coactivator, demonstrating a novel role for the Rho family of GTPases, including direct activation of a transcription factor and a mechanism for morphological changes associated with RAC3 overexpression. RAC3-modulated transcriptional activity may help explain the metastasis of some ERa þ positive breast cancers and the importance of the receptor as a mediator of metastasis.
Results

Identification of RAC3 as an ERa interacting protein by phage display
A phage display approach was used to identify both known and unknown ERa interacting proteins. The screen identified over 300 proteins with P-values under 0.05, including 27% of the previously identified ERa interactors listed in the Human Protein Resource Database (Keshava Prasad et al., 2009) . In vitro pull down and mammalian two hybrid approaches confirmed the interaction of ERa with 7 of the 10 tested proteins ( Supplementary Table 1 ). The low false positive rate demonstrates that this screening approach is a viable option for identifying potential nuclear receptor co-regulators.
RAC3 was identified as a putative ERa co-regulator by the phage display screen. Direct interaction of the two proteins was confirmed by in vitro pull down experiments using Sf-9 expressed and purified ERa (Invitrogen) as well as recombinantly expressed, HIStagged RAC3 (Figure 1a ). Analysis of three independent experiments confirmed that the RAC3/ERa interaction was estradiol dependent, and increased twofold in the presence of GTP (Figure 1b ). Ligand dependent ERa/ RAC3 interaction in cells was demonstrated by mammalian two-hybrid and co-immunoprecipitation experiments performed in ERa null, MCF7 C4-12 cells (Oesterreich et al., 2001) , with stably overexpressed Flag-ERa (Figures 1c and d) . GFP tagged RAC3 is ubiquitously expressed throughout the cell and localization is not altered by E2 treatment (data not shown). Notably, the highly homologous RAC family member RAC1 did not interact with ERa ( Figure 1c ). In total, these experiments show a direct, ligand dependent, GTP sensitive interaction between ERa and RAC3, but not RAC1.
RAC3 is a novel ERa co-activator When RAC3 was tested for its effect on ERa transcription using an ERE-luciferase reporter (Leong et al., 2005) , it increased E2-mediated ERE luciferase activity at both 6 and 24 h in MCF7 cells (Figure 2a ). Overexpression of RAC3, but not RAC1, increased E2- RAC3 is a pro-migratory co-activator of ERa MP Walker et al dependent ERa activation of ERE luciferase (Figure 2b ). The dominant negative RAC3 mutant, T17N, and its constitutively active mutant, RAC3 G12V, were tested for their ability to co-activate ERa (Mira et al., 2000) . As shown in Figure 2c , WT RAC3 and RAC3 G12V were comparably able to increase ERE luciferase activity in MCF7 cells. The dominant negative RAC3 T17N was significantly less active than WT RAC3, indicating that GTP is necessary for complete RAC3 induced activation of ERa. Similar results were observed in T47D cells, confirming that this phenotype is not cell-type specific (Supplementary Figure 1A) . Talukder et al., 2006 reported that Rho family GTPases transactivate ERa transcription through p21-activated protein kinase 1 (PAK1) . To test if RAC3 co-activation of ERa is independent of the PAK1 pathway, different mutants were used to block the PAK1 pathway. In the presence of a dominant negative PAK1 kinase dead mutant (PAK1 KD), RAC3 increased E2/ERa-mediated ERE luciferase activity in MCF7 cells (Figure 2d ). PAK1 has been reported to co-activate ERE luciferase by phosphorylating serine 305 in ERa, which resulted in subsequent phosphorylation of S118 . ERa constructs with S305A, S305E, and S104A, S106A and S118A mutations were co-transfected with RAC3 and ERE-luciferase constructs into MCF7 C4-12 cells. As shown in Supplementary figure 2A -C, phosphorylation mutants that block PAK1 induced phosphorylation and hyperactivation of the PAK1 pathway did not prevent RAC3 enhancement of E2-induced ERa transcription. These results demonstrate that RAC3 can co-activate E2-induced ERa transcription through a mechanism that is independent of the PAK1 pathway.
To confirm the results of the ERE luciferase reporter assays, the effect of RAC3 on E2/ERa-induced endogenous gene expression was studied. Cyclin D1 (CCND1) is a known ERa target gene with an important role in cell proliferation and tumor growth (Neuman et al., 1997) . As measured by quantitative reverse transcriptase-PCR, RAC3 overexpression caused an increase in E2-induced CCND1 transcript in MCF-7 cells (Figure 2e ). The presence of RAC3 at the CCND1 promoter was tested using ChIP assays. MCF7 C4-12 cells that stably expressed Flag-ERa were transiently transfected to overexpress RAC3 WT and RAC1 WT. An E2 dependent recruitment of RAC3 to the CCND1 promoter was observed (Figure 2f ), indicating that RAC3 is an important regulator of CCND1 expression. ERa occupancy at the TFF1 gene promoter also increased in the presence of estradiol and overexpressed RAC3 (Figure 2g ). These results illustrate that RAC3, but not RAC1, overexpression is able to enhance E2/ERa mediated transcription.
A single amino acid in RAC3 confers activation of ERa As seen in Figures 1c and 2a , RAC1 did not interact with ERa or co-activate E2/ERa-mediated ERE luciferase activity, despite its high sequence homology with RAC3. In MCF7 cells, RAC1 and RAC3 mRNA transcripts are expressed at comparable levels, as detected by quantitative reverse transcriptase-PCR (data not shown). RAC2 transcript was not detected in MCF7 cells (data not shown). RAC3 and RAC1 protein alignment shows that the two proteins differ by only 15 amino acids and that most of these differences map to the C terminus ( Figure 3a ). Based on the identification of functional motifs by ELM motif scan analysis, three mutations were introduced to test for differences between the two proteins (Gould et al., 2010) . The C terminus (residues 185-192) of RAC3 was converted to that of RAC1 (RAC3 C-TERM), a putative PKA phosphorylation site in RAC1 (S135) was introduced into RAC3 (RAC3 A135S) and a putative 14-3-3 binding site in RAC3 (S151) was mutated to correspond to RAC1 (RAC3 S151A). As measured by ERE luciferase assays, the only mutant that failed to coactivate ERa above vehicle control was RAC3 S151A (Figure 3b ). RAC1 overexpression produced a small increase in E2/ERa activity. However, as reported Figure 3 A single amino acid confers RAC3 co-activation of ERa. (a) Sequence alignment of RAC3 and RAC1. Boxed amino acids were mutated. (b, c) Mutations at S151 of RAC3 and RAC1 alter the ability of the GTPases to activate ERa-induced transcription as measured by ERE luciferase assay in MCF7 cells, which were transiently transfected with indicated constructs. (d) RAC3 S1515A mutation decreases the affinity of RAC3 for ERa in MCF7 C4-12 cells stably transfected with Flag-ERa and transiently transfected with RAC3 WT and RAC3 S151A. After a 1 h treatment with 10 nM E2, ERa was pulled down with H222.2 antibody. Western blot was probed with pan-RAC and ERa antibodies; all bands were taken from the same blot with empty wells omitted for clarity.
previously , RAC1 overexpression can activate the PAK1 pathway, thereby increasing ERa transcriptional activity. The effect seen by RAC3 is much more pronounced and is the result of a direct interaction with ERa, as shown in Figure 1 . As expected, the reciprocal RAC1 mutation (A151S) increased the ability of RAC1 to activate ERa transcription (Figure 3c ). The RAC3 S151A mutation does not alter RAC3 transfection efficiency or protein stability (Figure 3d and data not shown). Co-immunoprecipitation of E2-ERa and RCA3 showed a decreased interaction with the RAC3 S151A mutant compared with RAC3 WT (Figure 3d ). These results demonstrate that the ability of RAC3 to act as an ERa co-activator requires serine 151.
Knockdown and inhibition of RAC3 block ERa induced gene expression
To determine if RAC3 overexpression reflects endogenous RAC3 activity, a pan-RAC inhibitor, EHT 1864, was used. This inhibitor has previously been shown to specifically inhibit RAC1, RAC2 and RAC3 activities (Onesto et al., 2008) . As shown in Figure 4a , EHT 1864 exhibited a dose dependent inhibition of E2/ERa mediated ERE luciferase activity in MCF-7 cells, with maximal inhibition occurring at 5-10 mM EHT 1864. To confirm that this inhibition was mediated by RAC3, two unique RAC3 shRNAs were used to independently knock down RAC3 expression in MCF7 cells. Each shRNA reduced RAC3 mRNA expression by more than 60%, with no effect on ERa or RAC1 expression ( Figure 4b and data not shown). E2/ERa-mediated ERE transcription was significantly reduced in RAC3 knockdown cells (Figure 4c ), compared with control, indicating the importance of endogenous RAC3 as an ERa co-activator in MCF-7 cells. RAC1 knockdown had no effect on E2/ERa-mediated ERE transcription (Supplementary Figure 3B ). As expected, while EHT 1864 elicited a dose-dependent E2/ERa response in control knockdown cells, it was unable to inhibit E2/ERamediated transcriptional activity in RAC3 knockdown cells (Figure 4d ). These data are consistent with the RAC3 overexpression data and indicate that EHT 1864 can be used as an inhibitor of endogenous RAC3 coactivation of ERa. As shown in Figure 4e , EHT 1864 almost completely inhibited E2/ERa-induced expression of endogenous CCND1, TFF1, MTA1 but not FOS, indicating that RAC3 co-activation of ERa is gene selective. The interaction of ERa and RAC3 with the CCND1 and TFF1 promoters was confirmed by ChIP analysis (Figure 4f ). Similar to the gene expression data, EHT 1864 completely abrogated E2-induced ERa recruitment to TFF1 and CCND1 promoter sequences (Figure 4f ). RAC3 occupancy at the TFF1 promoter and at a previously described TFF1 enhancer sequence was also E2 sensitive ( Figure 4g ) (Pan et al., 2008) . RAC3 recruitment to the TFF1 promoter was blocked both by EHT 1864 and ICI 182,780, demonstrating that occupancy requires active RAC3 and is dependent upon E2/ERa (Figure 4g and data not shown). CCND1 gene expression was also significantly reduced in stable RAC3 knockdown cells, confirming the EHT 1864 inhibition of expression ( Figure 4h ). EHT 1864 also significantly antagonized E2-induced cell proliferation of MCF7 and T47D cells, confirming that abrogation of E2-induced CCND1 expression has phenotypic consequences (Figure 5a and Supplementary Figure 1B) . In agreement with the EHT 1864-induced antagonism, RAC3 knockdown significantly decreased E2-induced cell proliferation (Figure 5b ). In total, these results show convincingly that RAC3 is an important co-activator for a subset of ERa target genes and contributes significantly to E2-mediated MCF7 cell proliferation.
RAC3 is important for E2-induced cell migration RAC3 overexpression has been previously shown to increase the migratory potential of breast cancer cells (Baugher et al., 2005) . To test for an effect of RAC3 on ERa þ MCF-7 cell migration, cells were transfected with RAC3 WT, RAC3 S151A, RAC1 or vector alone, placed in transwells and treated with 10 nM E2. RAC3 WT increased cell migration twofold over vector alone (Figure 6a ). This increase was not observed for the RAC3 S151A mutant and was not seen in cells transfected with RAC1 ( Figure 6a ). As confirmation that this increase was ERa dependent, E2-induced migration was blocked by co-incubation with the complete ER antagonist ICI 182,780 (Figure 6b ). Treatment with the pan-RAC inhibitor EHT 1864 completely inhibited the E2-mediated MCF-7 cell migration, reducing it slightly below vehicle control, suggesting that RAC3 mediates basal migratory activity independent of ERa. In RAC3 knockdown cells, migration was significantly decreased compared with a control cell line (Figure 6c ). Also, EHT 1864 was unable to further inhibit migration in MCF7 RAC3 knockdown cells, confirming that endogenous RAC3 is fully responsible for this effect on ERa signaling (Figure 6c ).
RAC3 overexpression is an indicator of poor prognosis in human breast tumors
Using Oncomine (Compendia Bioscience, Ann Arbor, MI, USA), RAC3 overexpression correlates with invasive breast cancer in some data sets. Analysis of the NKI breast cancer patient database revealed the clinical relevance of RAC3 expression in ERa þ tumors (Chang et al., 2003) . Recurrence free survival was significantly shorter among women with ERa þ tumors that expressed RAC3 mRNA and this trend increased with increasing RAC3 mRNA expression ( Figure 7a ). RAC3 overexpression also increased the odds ratio for metastatic events by 6.09 in the highest RAC3 expressing ERa þ breast tumors (Figure 7c ). However, RAC3 mRNA expression did not correlate significantly with metastasis in ERa-tumor samples, although the sample size was not large enough to completely eliminate this possibility (data not shown). RAC1 mRNA expression did not correlate with an increase in metastasis or a decrease in recurrence free survival in ERa þ tumors (Figures 7b and d) .
Discussion
A phage display screen coupled with exon array analysis identified multiple known and novel ERa interacting proteins, whose interaction could be validated by in vitro pull down and mammalian two hybrid analyses. The low false positive rate demonstrates the efficacy of this technique for the identification of potential ER coregulators. The technique is also readily applicable to other nuclear receptors or any DNA binding protein.
Importantly, this technique allowed us to identify RAC3 as a novel and potent ERa co-regulator. The data presented here demonstrate a unique role for RAC3 as a critical co-activator of ERa mediated transcription. A combination of overexpression, chemical inhibition and shRNA knockdown data show that RAC3 is necessary for full activation of E2/ERainduced expression of genes known to be involved in is required for EHT 1864-mediated antagonism of ERE luciferase. RAC3 knockdown MCF7 cells were treated with 10 nM E2±1 mM ICI or increasing concentrations of EHT 1864. (e) EHT 1864 inhibits ERa target genes CCND1, MTA1 and TFF1. Cells were pretreated for 5 min with 1 mM ICI, 5 mM EHT 1864 or vehicle before addition of 10 nM E2. RNA was isolated by Trizol and mRNA expression was determined by quantitative reverse transcriptase-PCR using TAQMAN assays. (f, g) MCF7 C4-12 cells stably transfected with Flag-ERa were grown in 2.5% stripped serum for 1 day and then serum starved overnight. Cells were treated with 10 nM E2 and ERa was immunoprecipitated from cell extracts with H222.2 (f), or RAC3 was immunoprecipitated with a pan-RAC antibody (g). Gene occupancy was determined by real time PCR at the CCND1, TFF1 promoter and TFF1 enhancer. (h) RAC3 knockdown decreases CCND1 gene expression as measured by TAQMAN assay.
RAC3 is a pro-migratory co-activator of ERa MP Walker et al cell proliferation, migration and invasion. In addition, analysis of the NKI database showed that RAC3 expression correlates with poor prognosis for women with ERa þ tumors, and a decrease in recurrence free survival. The clinical data are consistent with the molecular data, which show that RAC3, but not RAC1, is a co-activator of ERa target genes that are involved in the proliferation or migration of hormonesensitive breast cancers. RAC3 knockdown in MCF7 cells showed that it was critical for full ERa transcriptional activity. ERa activity in ERE-luciferase reporter assays and for E2induced CCND1 gene expression was reduced by B50% in RAC3 knockdown cells, compared with control knockdowns. EHT 1864 completely abolished ERa recruitment to the CCND1 promoter as well as E2/ ERa-mediated CCND1 gene expression. Given the absence of an additional effect of EHT 1864 in RAC3 knockdown cells, RAC3 appears to be both necessary for full E2/ERa activity on CCND1 expression at early time points following E2 exposure.
The absence of ERa co-regulatory activity for RAC1 versus RAC3 is another example of the previously observed opposing effects of these two highly homologous proteins (Hajdo-Milasinovic´et al., 2007) . In the current study, this difference was mapped to RAC3 S151, which corresponds to A151 in RAC1 (Figure 3) . Although S151 is also present in RAC2, RAC2 is not expressed in MCF7 or C4-12 cells. As identified by ELM motif analysis, S151 is a putative 14-3-3 binding site. Computational analysis with PROSITE and NetPHOS 2.0 indicate that S151 is a putative protein kinase C phosphorylation site that has a high likelihood of being phosphorylated (Blom et al., 1999) . S151 has no previously reported effect on the activity of RAC3 and therefore represents a novel functional motif for RAC3. RAC3 overexpression in MCF-7 cells correlated with a pro-growth, pro-migratory phenotype ( Figures  5 and 6 ). E2-induced expression of CCND1, TFF1 and MTA1 has known cell growth, cell motility and cell invasive consequences in breast cancer cells (Neuman et al., 1997; Prest et al., 2002; Gururaj et al., 2006) . In the current study, RAC3-enhanced E2/ERa induced CCND1, TFF1 and MTA1 gene expression correlated with changes in cell proliferation and migration. RAC3 overexpression enhanced E2-dependent migration of MCF7 cells and expression of CCND1, whereas inhibition of RAC3 activity either with EHT 1864 or RAC3 shRNA inhibited E2-induced migration of MCF7 cells and induction of CCND1, TFF1 and MTA1 mRNA. ERa can induce cell migration through both genomic and non-genomic mechanisms (Sanchez et al., 2010) . Although the genomic data presented here clearly demonstrate that RAC3 activity alters the expression of pro-migratory genes, it is also possible that RAC3 can modulate extra nuclear ERa activities that affect cell proliferation, migration or invasion. This possibility was not explored. Also, because overexpression of RAC3 can increase the migration and invasion of breast cancer cells independent of ERa (Baugher et al., 2005; Chan et al., 2005) , at least two pathways must exist for RAC3mediated tumor cell migration.
Although numerous known ERa co-regulators have been described, many of these proteins are not useful drug targets. Previous work on ER/co-regulator-based drug discovery focused primarily on the development of selective estrogen receptor modulators that function by binding directly with ERa to recruit or block co-regulator binding to ERa, thereby activating or repressing ERa gene targets that contribute to a particular outcome (Hall and McDonnell 2005) . Our data demonstrate that some ERa co-activators, like RAC3, can be inhibited directly with small molecules to block the activity of the receptor. This approach could lead to the establishment of a new, potentially complementary, class of ERa antagonists that act indirectly on the receptor to block E2-induced activation.
Rho family GTPases are best known as integral regulators of the actin cytoskeleton (Heasman and Ridley, 2008) . As a consequence, Rho family GTPases have important roles in transcriptional regulation through the modulation of actin dynamics and by activating signaling cascades (Jaffe and Hall, 2005) . The data presented here demonstrate a novel role for Rho family GTPases as direct transcriptional co-activators.
In summary, the small Rho GTPase RAC3 was identified as an ERa co-activator that can promote E2induced migration and is required for full activation of ERa on a subgroup of genes in MCF7 cells. This activity of RAC3 as a transcriptional co-activator represents a novel function for Rho-family GTPases and a potential new target as a treatment option for ERa positive breast cancers that become therapy resistant. Figure 7 Clinical consequences of RAC3 expression in ERa positive human breast tumors. Gene expression data were obtained from the NKI patient database. (Chang et al., 2003; Chang et al., 2005) All analysis was done using Prism 5 for Mac OS X from GraphPad (La Jolla, CA, USA). (a, b) Increasing RAC3 expression decreases recurrence free survival shown in Kaplan-Meier curves of recurrence free survival in years. Increasing RAC1 expression had no effect. (c, d) Increasing RAC3 expression increases the proportion of patients with metastatic events. RAC1 expression levels had no statistically significant effect.
Materials and methods
Chemicals and antibodies
RAC3 is a pro-migratory co-activator of ERa MP Walker et al Biosynth (Itasca, IL, USA). Full-length ERa was purchased from Invitrogen (Carlsbad, CA, USA). All western blots were performed using LiCOR secondary antibodies according to manufacturer's instructions (Lincoln, NE, USA).
Plasmids
The pRK5 RAC3 WT, T17 and V12 were gifts of Ulla Knauss (University College Dublin, Dublin, Ireland). PAK1 kinase dead mutant was a gift of Dr Piers Nash (University of Chicago, Chicago, IL, USA). ERa S305A and ERa S305E mutants were gifts of Dr Rakesh Kumar (George Washington University, Washington D.C., USA). The ERa S106A, S108A and S118A mutant were gifts of Dr Didier Picard (University of Geneva, Geneva, Switzerland). RAC1, RAC3 and all of the other co-regulators identified by the phage display screen were obtained in pDONR223 from the Human ORFeome collection at the Functional Genomics Facility at the University of Chicago. PGL2-ERE-luciferase and pM-GWB were gifts of Dr Donald McDonnell (Duke University, Durham, NC, USA). The pMGWB-RAC1, pMGWB-RAC3 and pDEST40-RAC3 were cloned by Gateway cloning. The pRK5-RAC1 and pDEST527 were obtained from Addgene (Cambridge, MA, USA). All other RAC3 and RAC1 mutations were made by site-directed mutagenesis (Stratagene, Santa Clara, CA, USA). Full-length ERa was cloned into the pACT vector (Promega, Madison, WI, USA) by restriction enzyme digestion (Madison, WI, USA). The pRL-TK renilla control vector was purchased from Promega.
Cell culture
All cells were grown at 37 1C in 5% CO 2 . MCF7 human breast cancer cells, obtained from the ATCC, and ERa negative MCF7 C4-12 cells, obtained from Wade Welshons (University of Missouri, Columbia, MO, USA), were maintained in high glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) (Oesterreich et al., 2001) . T47D cells were obtained from the ATCC and maintained in RPMI supplemented with 10% FBS. MCF7 K1 cells were grown in high glucose Dulbecco's modified Eagle's medium supplemented with 10% stripped media. MCF7 J2 cells were obtained from Essen Biosciences (Ann Arbor, MI, USA) and grown in Minimal Essential Medium with 10% FBS and 5 mg/ ml blasticidin. C4-12 þ Flag-ERa cells were made by retroviral infection and grown in high glucose Dulbecco's modified Eagle's medium supplemented with 10% FBS and 0.6 mg/ml puromycin.
Mammalian two-hybrid A total of 30 000 MCF7 C4-12 cells were seeded in 48-well dishes and transfected with equal amounts of pSG-5 luciferase, GAL-4 vector, VP-16 ER, and RTK using Lipofectamine 2000 from Invitrogen according to manufacturer's instructions. The plates were read using a home made dual luciferase protocol as described previously (Hampf and Gossen, 2006 ) on a Wallac Microbeta Jet luminometer (Perkin Elmer, Downers Grove, IL, USA).
In-vitro pull down
Recombinantly expressed HIS-tagged RAC3 was expressed in pDEST-527 obtained from Dr Dominic Esposito (National Cancer Institute, Betheseda, MD, USA). Full-length ERa (Invitrogen) was preincubated with ligands at a final concentration of 100 nM. RAC3 protein was preincubated with either GTP or GDP at a final concentration of 100 mM. Proteins were combined to achieve a final concentration of 10 mM for RAC3 and 100 nM for ERa. The mixture was gently rocked at 4C for 2 h. A volume of 50 ml of prewashed Talon beads (Clontech, Mountain View, CA, USA) were then added to each tube and incubated for 1 h at 4C while rocking gently. The beads were pelleted by centrifugation, washed three times with GBB buffer and bound proteins were eluted in 2x sample buffer. Proteins were resolved by SDS-polyacrylamide gel electrophoresis and analyzed on western blots using the LiCOR system. ERa bands were normalized to the pulled down RAC3 bands.
Luciferase assays
Cells were transfected using Lipofectamine 2000 and Lipofectamine LTX from Invitrogen for MCF7 C4-12 and MCF7 cells, respectively, according to the manufacturer's instructions. Cells were transfected with 0.4 ng of pGL2-ERE luciferase, 0.2 ng of pRL-TK vector as a transfection control and 0.4 ng of gene constructs per well. Cells were treated with ligands for 24 h in either 10% stripped serum or 2.5% stripped serum. MCF7 C4-12 cells were read using homemade dual luciferase as described previously (Hampf and Gossen, 2006) . To increase signal, MCF7 and T47D cells were read using the Promega Dual Luciferase Kit (Promega) according to manufacturer's instructions.
short-hairpin (sh) RNA knockdown Five RAC3 pLKO vector based shRNA clones, six RAC1 GIPZ shRNAmir based clones, and the non-silencing-GIPZ-shRNAmir control were obtained from Open Biosystems (Huntsville, AL, USA). The pLKO-SHC control, VSV-G and DR plasmids were obtained from Piers Nash (University of Chicago). Five different clones for RAC3 and a SHC control were generated in MCF7 Cells. Cells were infected using the protocol from the RNAi Consortium at the Broad Institute (Moffat et al., 2006) .
ChIP
ChIP assays were done as previously described by the Brown lab (Shang et al., 2000) . For more detail and primers see Supplementary Methods.
Coimmunoprecipitation MCF7 C4-12 þ FLAG ERa cells were grown in 100 mm plates. Cells were transfected with plasmids in 10% stripped serum with Fu gene as per manufacturer's instruction. Cells were serum starved overnight, treated in 10% stripped serum with either 10 nM E2 or vehicle alone for 1 h, and lysed in TMN (Tris-MgCl 2 -NaCl) buffer. Cell extracts were analyzed by SDS-polyacrylamide gel electrophoresis and western blots were imaged using the LiCOR system. For a more detailed immunoprecipitation protocol, please see the Supplementary Methods.
Real-time PCR MCF7 cells were plated in six-well dishes. Before transfections, cells were washed with phosphate-buffered saline and grown in 2.5% serum. Cells were transfected overnight using Fu gene in 2.5% stripped serum Dulbecco's modified Eagle's medium as per manufacturer's instruction. Cells were then grown in stripped serum for 2 days with daily media changes. For endogenous gene assays, cells were grown in 2.5% stripped serum for 3 days with daily media changes and then serum starved overnight before treatment. Cells were preincubated with indicated concentrations of ICI 182,780 or EHT 1864 for 15 min before the addition of 10 nM E2 for 2 h. Complementary DNA was made using Superscript Vilo cDNA Synthesis kit (Invitrogen) as per manufacturer's instruction. Real-time PCR was done using an Applied Biosystems Step One Plus 96 well
